GlassScriptPhysician profile
Phuong Trinh
NPI 1679536486
$196,006.98
in general payments reported to CMS, 2019-2025
24 companies · $8,390 in 2025
The $8,390 reported for 2025 was more than what 92% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $10K · 2021: $15K · 2022: $11K · 2023: $57K · 2024: $62K · 2025: $8,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $108K · Food and Beverage: $8,520 · Consulting Fee: $7,410 · Travel and Lodging: $3,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $107,915.00 |
| Food and Beverage | $8,520.34 |
| Consulting Fee | $7,410.00 |
| Travel and Lodging | $3,229.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $97,447.90 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $91,366.36 | 2019-2025 | Biktarvy, Sunlenca |
| Abbvie INC. | $1,365.18 | 2019-2025 | Avycaz |
| Merck Sharp & Dohme LLC | $923.28 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Insmed, INC. | $762.37 | 2019-2024 | Arikayce |
| Adaptive Biotechnologies Corporation | $756.59 | 2020 | |
| Janssen Biotech, INC. | $592.36 | 2019-2023 | Symtuza |
| Janssen Products, LP | $540.01 | 2019-2021 | |
| Theratechnologies INC. | $539.84 | 2019-2025 | Egrifta, Trogarzo, Egrifta Sv |
| La Jolla Pharmaceutical Company | $332.94 | 2022-2025 | Xerava, Xacduro |
| Cipla USA INC. | $277.77 | 2021 | |
| Alexion Pharmaceuticals, INC. | $233.90 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $209.52 | 2019-2023 | Nuzyra |
| Napo Pharmaceuticals INC | $186.79 | 2019-2022 | |
| Shionogi INC | $114.79 | 2022-2024 | Fetroja |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Comsort, INC | $100.00 | 2019 | |
| Allergan, INC. | $57.55 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.09 | 2024 | |
| Melinta Therapeutics, LLC | $31.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Janssen Scientific Affairs, LLC | $25.20 | 2019 | |
| Pfizer INC. | $23.88 | 2022 | |
| Mylan Institutional INC. | $20.59 | 2019 | |
| Fortovia Therapeutics, INC. | $16.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuong Trinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.